MD20170048A2 - Abiraterone acetate formulation and methods of use - Google Patents

Abiraterone acetate formulation and methods of use Download PDF

Info

Publication number
MD20170048A2
MD20170048A2 MDA20170048A MD20170048A MD20170048A2 MD 20170048 A2 MD20170048 A2 MD 20170048A2 MD A20170048 A MDA20170048 A MD A20170048A MD 20170048 A MD20170048 A MD 20170048A MD 20170048 A2 MD20170048 A2 MD 20170048A2
Authority
MD
Moldova
Prior art keywords
methods
abiraterone acetate
acetate formulation
formulation
compositions
Prior art date
Application number
MDA20170048A
Other languages
Romanian (ro)
Russian (ru)
Inventor
Маура МЕРФИ
Пол НЕМЕТ
Х. Уилльям Бош
Мэттью КАЛЛАХАН
Сатья БХАМИДИПАТИ
Джейсон КОУЛМАН
Кристофер ХИЛЛ
Марк Норрет
Original Assignee
Iceutica Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55533897&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD20170048(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US14/707,922 external-priority patent/US20150246060A1/en
Application filed by Iceutica Inc. filed Critical Iceutica Inc.
Publication of MD20170048A2 publication Critical patent/MD20170048A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)

Abstract

The invention relates to pharmaceutical compositions, including unit dosage forms, comprising abiraterone acetate and methods for producing and using such compositions.
MDA20170048A 2014-09-18 2015-09-18 Abiraterone acetate formulation and methods of use MD20170048A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462052294P 2014-09-18 2014-09-18
US14/707,922 US20150246060A1 (en) 2013-03-15 2015-05-08 Abiraterone Acetate Formulation and Methods of Use
PCT/US2015/050889 WO2016044701A1 (en) 2014-09-18 2015-09-18 Abiraterone acetate formulation and methods of use

Publications (1)

Publication Number Publication Date
MD20170048A2 true MD20170048A2 (en) 2017-08-31

Family

ID=55533897

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20170048A MD20170048A2 (en) 2014-09-18 2015-09-18 Abiraterone acetate formulation and methods of use

Country Status (17)

Country Link
EP (1) EP3193857A4 (en)
JP (1) JP2017528457A (en)
KR (2) KR102617537B1 (en)
CN (1) CN106687112A (en)
AP (1) AP2017009804A0 (en)
AU (1) AU2015317466A1 (en)
BR (1) BR112017003219A2 (en)
CA (1) CA2958316A1 (en)
CO (1) CO2017002472A2 (en)
EA (1) EA201790650A1 (en)
IL (1) IL250270B (en)
MD (1) MD20170048A2 (en)
MX (1) MX2017003525A (en)
PH (1) PH12017500239A1 (en)
SG (1) SG11201701139YA (en)
TN (2) TN2017000098A1 (en)
WO (1) WO2016044701A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3280448B1 (en) 2015-04-10 2020-12-30 Capsugel Belgium NV Abiraterone acetate lipid formulations
CN110891549A (en) 2017-04-07 2020-03-17 玛亚实验室公司 Methods of improving solubility and bioavailability of therapeutic agents
CN113473974A (en) * 2019-01-25 2021-10-01 深圳市药欣生物科技有限公司 Pharmaceutical composition
CA3131034A1 (en) 2019-03-06 2020-09-10 Matthew J. Sharp Abiraterone prodrugs
CN110742870B (en) * 2019-12-04 2021-04-20 武汉大学 Abiraterone acetate preparation and preparation method thereof
CN111110646A (en) * 2020-02-19 2020-05-08 纳兰迦(上海)生物医药科技有限公司 Prescription and preparation method of low-specification abiraterone acetate oral preparation
CN113384542B (en) * 2020-03-14 2024-03-29 鲁南制药集团股份有限公司 Tablet of steroid CYP17 inhibitor solid dispersion and preparation method thereof
KR20220166856A (en) * 2020-04-16 2022-12-19 타반타 테라퓨틱스 헝가리 인코포레이티드 Methods and compositions for treating prostate cancer
CA3177094A1 (en) * 2020-05-08 2021-11-11 Janssen Pharmaceutica Nv Treatment of prostate cancer with a combination of abiraterone acetate and niraparib
EP3944860A1 (en) 2020-07-30 2022-02-02 Galenicum Health S.L.U. Abiraterone for use in a method of treating cancer
CA3207282A1 (en) 2021-02-15 2022-08-18 Matthew J. Sharp Abiraterone prodrugs
KR20240044329A (en) 2022-09-28 2024-04-04 한미약품 주식회사 Oral composite tablet comprising abiraterone acetate and prednisolone
KR20240145412A (en) 2023-03-27 2024-10-07 한미약품 주식회사 Pharmaceutical formulation comprising abiraterone acetate and prednisolone and method for preparing same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6141013B2 (en) * 2009-04-24 2017-06-07 イシューティカ ピーティーワイ リミテッド Production of encapsulated nanoparticles on a commercial scale
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
WO2014009436A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Nanosuspension of abiraterone acetate
WO2014009437A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Oxidation stability of abiraterone acetate
WO2014009434A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate
CN102743393A (en) * 2012-07-27 2012-10-24 海南盛科生命科学研究院 Medicinal composition containing abiraterone acetate and preparation technology thereof
TWI686212B (en) * 2013-03-15 2020-03-01 阿聯商太陽法瑪全球有限公司 Abiraterone acetate formulation

Also Published As

Publication number Publication date
KR20230014878A (en) 2023-01-30
TN2017000098A1 (en) 2018-10-19
KR20170070025A (en) 2017-06-21
KR102617537B1 (en) 2023-12-22
IL250270A0 (en) 2017-03-30
JP2017528457A (en) 2017-09-28
IL250270B (en) 2021-02-28
CO2017002472A2 (en) 2017-07-11
EP3193857A4 (en) 2018-04-11
MX2017003525A (en) 2017-06-21
BR112017003219A2 (en) 2017-11-28
CA2958316A1 (en) 2016-03-24
WO2016044701A1 (en) 2016-03-24
AP2017009804A0 (en) 2017-03-31
AU2015317466A1 (en) 2017-02-23
PH12017500239A1 (en) 2017-07-03
SG11201701139YA (en) 2017-03-30
EA201790650A1 (en) 2017-07-31
CN106687112A (en) 2017-05-17
KR102491439B1 (en) 2023-01-25
EP3193857A1 (en) 2017-07-26
TN2018000318A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
ZA202004557B (en) Modulatory polynucleotides
MD20170048A2 (en) Abiraterone acetate formulation and methods of use
IL269444B (en) New substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs
TW201613901A (en) New compounds
MY187540A (en) Compounds active towards bromodomains
NZ712350A (en) Abiraterone acetate formulation
PH12016501830A1 (en) Inhibitors of c5a for the treatment of viral pneumonia
IL253793B (en) Complexes of abiraterone acetate, process for the preparation thereof and pharmaceutical compositions containing them
MX2017002816A (en) Pyrazolopyridine derivatives and their use in therapy.
PH12016501686A1 (en) Pharmaceutical compositions of sitagliptin
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
IN2013MU03641A (en)
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
IN2014CH00840A (en)
EP3151826A4 (en) Omega-3 compositions, dosage forms, and methods of use
MX2015016603A (en) Corticosteroid compositions.
HK1234671A1 (en) Omega-3 compositions, dosage forms, and methods of use

Legal Events

Date Code Title Description
FA9A Abandonment or withdrawal of application (patent for invention)